Cargando…

Specialty and cancer drugs set to drive US drug expenditure in 2021

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085802/
https://www.ncbi.nlm.nih.gov/pubmed/33948077
http://dx.doi.org/10.1007/s40274-021-7669-0
_version_ 1783686419313590272
collection PubMed
description
format Online
Article
Text
id pubmed-8085802
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80858022021-04-30 Specialty and cancer drugs set to drive US drug expenditure in 2021 PharmacoEcon Outcomes News Clinical Study Springer International Publishing 2021-05-01 2021 /pmc/articles/PMC8085802/ /pubmed/33948077 http://dx.doi.org/10.1007/s40274-021-7669-0 Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Clinical Study
Specialty and cancer drugs set to drive US drug expenditure in 2021
title Specialty and cancer drugs set to drive US drug expenditure in 2021
title_full Specialty and cancer drugs set to drive US drug expenditure in 2021
title_fullStr Specialty and cancer drugs set to drive US drug expenditure in 2021
title_full_unstemmed Specialty and cancer drugs set to drive US drug expenditure in 2021
title_short Specialty and cancer drugs set to drive US drug expenditure in 2021
title_sort specialty and cancer drugs set to drive us drug expenditure in 2021
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085802/
https://www.ncbi.nlm.nih.gov/pubmed/33948077
http://dx.doi.org/10.1007/s40274-021-7669-0